NCT06626126Not yet recruiting
Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergoing Percutaneous Coronary Intervention
Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergoing Percutaneous Coronary Intervention: a Multicenter, Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 16 Oct 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This multicenter randomized trial is designed to assess the efficacy of lipid-lowering therapy in patients undergoing percutaneous coronary intervention, comparing an Apolipoprotein B-targeted approach with a Low-Density Lipoprotein Cholesterol (LDL-C)-targeted approach. The primary outcomes are to evaluate the proportion of patients achieving lipid-lowering treatment goals at the 1-year follow-up between the two treatment strategies: Apolipoprotein B-based therapy versus LDL-C-based therapy.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 1448 (estimated)
- First submitted
- 1 Oct 2024
- Start date
- 1 Jan 2025
- Primary completion date
- 1 Jan 2028
- Lead sponsor
- University Medical Center Ho Chi Minh City (UMC)
- Diseases
- Coronary artery disease
- NCT number
- NCT06626126
What you commit to
- Study type: Interventional
- Planned participants: 1448
- From 1 Jan 2025 to the primary completion date, 1 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with contraindication to statin or other lipid-lowering therapy.
Other illness
- Limited life expectancy: patients with a life expectancy of less than 12 months due to other non-cardiac conditions.
- Liver Disease: patients with cirrhosis or significant liver dysfunction.
- Any condition that may interfere with the study process, including treatment adherence or follow-up appointments (e.g., dementia, alcohol abuse, severe debilitation, long distances required for follow-up, etc.).
Other
- Inability to Provide Informed Consent: Patients who are unable or unwilling to provide consent.
Who the study is looking for
- Patients aged 18 years or older.
- Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).
- Patients who agree to participate and provide informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Medical Center Ho Chi Minh City Coordinator of this site? Confirm its status | Ho Chi Minh City | Vietnam | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.